Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...

Following this approval, Sarclisa is the first anti-CD38 therapy in combination with VRd for treating transplant-ineligible NDMM patients. A regulatory filing is currently under review in the EU ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

Justin Welby, the leader of 85 million Anglicans worldwide, announced his resignation days after a report found he had taken insufficient action over claims of abuse. By Stephen Castle and Mark ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...

Voting is underway in Kerala's Wayanad Lok Sabha constituency for the by-election. Congress leader Priyanka Gandhi Vadra is making her electoral debut against 15 other candidates. The bypoll was ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

CD38单抗赛道的“后来者”还有不少，渤健/天境生物的Felzartamab（菲泽妥单抗）、武田制药的Mezagitamab等也在加速追赶，形成“一超多强”的市场竞争格局。

Melania Trump declined Jill Biden's invitation for tea at the White House as their husbands meet for the customary post-election lunch. Melania reportedly cited a scheduling conflict but sources ...